New Edge Advisors, LLC Halozyme Therapeutics, Inc. Transaction History
New Edge Advisors, LLC
- $11.2 Billion
- Q1 2024
A detailed history of New Edge Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 355 shares of HALO stock, worth $18,602. This represents 0.0% of its overall portfolio holdings.
Number of Shares
355
Previous 462
23.16%
Holding current value
$18,602
Previous $17,000
17.65%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding HALO
# of Institutions
441Shares Held
122MCall Options Held
216KPut Options Held
140K-
Black Rock Inc. New York, NY18.2MShares$956 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$684 Million0.01% of portfolio
-
State Street Corp Boston, MA6.49MShares$340 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.12MShares$216 Million3.73% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.79MShares$199 Million0.24% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.3B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...